ARTICLE | Clinical News
Pharmos data
June 28, 1993 7:00 AM UTC
Pharmos Corp. (PARS) Pharmos Corp. (PARS) presented data from a 110-patient Phase II/III study of loteprednol etabonate, a corticosteroid to treat giant papillary conjunctivitis, an inflammatory cond...